Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Oct 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called penicillamine in helping patients with recurrent head and neck cancer respond better to radiation therapy. Researchers believe that copper buildup in the body can make cancer cells resistant to radiation, and penicillamine is used to lower copper levels. By doing this, they hope to make the cancer cells more sensitive to the treatment.

To participate in this trial, individuals must be between 18 and 75 years old and have already received standard radiation or chemotherapy for their cancer. They should have head and neck tumors that have returned after treatment, confirmed by medical tests. Participants will need to sign a consent form and undergo some health checks to ensure they are suitable for the study. It's important to know that not everyone will be eligible; for example, those who are pregnant, breastfeeding, or allergic to penicillamine will not be able to join. If you decide to participate, you can expect close monitoring and support from the medical team throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign informed consent
• • 2. The age is 18-75 years
• • 3. Previously received standard radical radiotherapy or chemoradiotherapy
• • 4. Head and neck tumors with in situ or cervical lymph node recurrence confirmed by pathological biopsy and imaging examination
• • 5. ECOG PS：0/1
• • 6. Laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment.
• Exclusion Criteria:
• • 1. After evaluation, it does not meet the indications of re-radiotherapy
• • 2. Unable to take oral medication
• • 3. Pregnancy or lactation
• • 4. Known allergy to penicillamine
• • 5. Patients who are judged by the researcher as unsuitable to participate in this trial.